Safer shield for transplant patients? new drug aims to block dangerous virus
NCT ID NCT07266467
Summary
This study is testing a new drug called leymovir to prevent cytomegalovirus (CMV) infection in people who have recently received a kidney transplant. It will compare leymovir to the current standard drug, valganciclovir, in 290 Chinese patients to see if it works as well and is safer, with fewer side effects like bone marrow problems. The goal is to find a better way to protect transplant patients from this serious viral infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Xi 'an Jiaotong University
RECRUITINGXi'an, Shaanxi, 710000, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.